Arterys and iCAD join forces to roll out breast health AI solutions worldwide

Arterys and iCAD are joining forces to expand access to AI-powered breast health solutions worldwide, the companies announced Tuesday.

This partnership will enable iCAD to add Arterys’ FDA-cleared MICA platform to its installed base and give providers access to their software from anywhere in the world. 

Company representatives commended Arterys' integration capabilities. As the world’s first internet platform for medical imaging, its online setup takes hours compared to the weeks or months often required to configure onsite IT solutions. 

“Arterys has a decade of cloud-native expertise and combining this with iCAD's best-of-breed breast AI and risk solutions, we will be able to serve any customer, anywhere, anytime via the internet,” explained Dan Arnoff, the company's senior vice president of Commercialization.  

iCAD offers several breast imaging solutions, including its Profound AI for DBT software, which the company says is clinically proven to reduce radiologists’ reading time, increase sensitivity and decrease patient recall rates. 

"We are pleased that our technology will soon be integrated directly within the Arterys platform, offering seamless interoperability and expanding access to this leading-edge technology to more facilities and imaging centers worldwide," said Stacey Stevens, president of iCAD.

You can learn more about the global distribution agreement between Arterys and iCAD here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Around the web

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. 

This two-year analysis of the FISH&CHIPS study found that using advanced AI from Heartflow to evaluate cardiac CT is safe, effective and limits the use of unnecessary follow-up tests.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday.